论文部分内容阅读
目的 :探讨Graves病患者血清可溶性CD8抗原 (sCD8)测定的临床意义。方法 :参照国外文献 ,建立了人血清sCD8测定的酶联免疫吸附实验 (ELISA)方法。测定 40例正常人及 46例GD患者血清sCD8含量并作动态观察。结果 :GD组治疗前血清sCD8水平显著高于对照组 ,经丙基硫氧嘧啶 (PTU)治疗 2～ 7月后 ,病情缓解者sCD8明显下降 ,与治疗前有显著性差异 (P <0 0 0 1) ,而未缓解者持高不降。血清sCD8与T3、T4、TSH、TGA、TMA均无相关性。结论 :血清sCD8水平与GD病情活动性有一定相关性 ,并可能对预后判断有价值。PTU显示免疫抑制作用。
Objective: To investigate the clinical significance of serum soluble CD8 antigen (sCD8) in patients with Graves disease. Methods: With reference to foreign literature, an ELISA method of human serum sCD8 was established. Serum levels of sCD8 in 40 normal subjects and 46 patients with GD were measured and observed. Results: The level of sCD8 in GD group was significantly higher than that in control group. After treated with propylthiouracil (PTU) for 2 ~ 7 months, the sCD8 level in patients with euthyroidism was significantly lower than that in control group (P <0 0 0 1), while those who did not alleviate high and not decrease. There was no correlation between serum sCD8 and T3, T4, TSH, TGA and TMA. Conclusion: The level of sCD8 in serum is related to the activity of GD and may be of value to prognosis. PTU shows immunosuppressive effects.